Caissa Capital Management ltd., 10% Owner at Avalo Therapeutics, Inc. (AVTX), bought 844 shares at $2.87 ($2K) on 2023-05-31, disclosed to the SEC on 2023-06-02.
Open-market purchase of $2k AVTX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| Filing → |
| AVTX | BUY | 2023-06-14 | $64K | — | Filing → |
| AVTX | BUY | 2023-06-09 | $56K | — | Filing → |
| AVTX | BUY | 2023-05-30 | $7K | — | Filing → |